Opinion | March 24, 2022
Seven ways the pharma industry can benefit from tech-driven logistics solutions
The next-gen logistics management solutions are making the global supply chains more customer-centric and sustainable
The next-gen logistics management solutions are making the global supply chains more customer-centric and sustainable
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Machine learning approach to systems biology combined with ligand discovery platform
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
New inhalers would have near-zero Global Warming Potential propellant
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Subscribe To Our Newsletter & Stay Updated
